These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 18718210)

  • 1. Cognitive impairment in schizophrenia: a review of developmental and genetic models, and pro-cognitive profile of the optimised D(3) > D(2) antagonist, S33138.
    Millan MJ; Brocco M
    Therapie; 2008; 63(3):187-229. PubMed ID: 18718210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. S33138 (N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1] benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenyl-acetamide), a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: III. Actions in models of therapeutic activity and induction of side effects.
    Millan MJ; Loiseau F; Dekeyne A; Gobert A; Flik G; Cremers TI; Rivet JM; Sicard D; Billiras R; Brocco M
    J Pharmacol Exp Ther; 2008 Mar; 324(3):1212-26. PubMed ID: 18096759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: I. Receptor-binding profile and functional actions at G-protein-coupled receptors.
    Millan MJ; Mannoury la Cour C; Novi F; Maggio R; Audinot V; Newman-Tancredi A; Cussac D; Pasteau V; Boutin JA; Dubuffet T; Lavielle G
    J Pharmacol Exp Ther; 2008 Feb; 324(2):587-99. PubMed ID: 18024789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent. II. A neurochemical, electrophysiological and behavioral characterization in vivo.
    Millan MJ; Svenningsson P; Ashby CR; Hill M; Egeland M; Dekeyne A; Brocco M; Di Cara B; Lejeune F; Thomasson N; Munoz C; Mocaër E; Crossman A; Cistarelli L; Girardon S; Iob L; Veiga S; Gobert A
    J Pharmacol Exp Ther; 2008 Feb; 324(2):600-11. PubMed ID: 18024787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The dopamine D3 receptor antagonist, S33138, counters cognitive impairment in a range of rodent and primate procedures.
    Millan MJ; Buccafusco JJ; Loiseau F; Watson DJ; Decamp E; Fone KC; Thomasson-Perret N; Hill M; Mocaer E; Schneider JS
    Int J Neuropsychopharmacol; 2010 Sep; 13(8):1035-51. PubMed ID: 20663270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cariprazine, an orally active D2/D3 receptor antagonist, for the potential treatment of schizophrenia, bipolar mania and depression.
    Gründer G
    Curr Opin Investig Drugs; 2010 Jul; 11(7):823-32. PubMed ID: 20571978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism.
    Neill JC; Barnes S; Cook S; Grayson B; Idris NF; McLean SL; Snigdha S; Rajagopal L; Harte MK
    Pharmacol Ther; 2010 Dec; 128(3):419-32. PubMed ID: 20705091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Functional role of dopamine D3 receptor in schizophrenia].
    Semba J
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2004 Feb; 24(1):3-11. PubMed ID: 15027325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blockade of dopamine D(3) receptors in frontal cortex, but not in sub-cortical structures, enhances social recognition in rats: similar actions of D(1) receptor agonists, but not of D(2) antagonists.
    Loiseau F; Millan MJ
    Eur Neuropsychopharmacol; 2009 Jan; 19(1):23-33. PubMed ID: 18793829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of dopamine D(3) receptors in antipsychotic activity and cognitive functions.
    Gross G; Drescher K
    Handb Exp Pharmacol; 2012; (213):167-210. PubMed ID: 23027416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blockade of dopamine D₃ but not D₂ receptors reverses the novel object discrimination impairment produced by post-weaning social isolation: implications for schizophrenia and its treatment.
    Watson DJ; Marsden CA; Millan MJ; Fone KC
    Int J Neuropsychopharmacol; 2012 May; 15(4):471-84. PubMed ID: 21414250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopamine D₃ receptor antagonism--still a therapeutic option for the treatment of schizophrenia.
    Gross G; Wicke K; Drescher KU
    Naunyn Schmiedebergs Arch Pharmacol; 2013 Feb; 386(2):155-66. PubMed ID: 23128852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The neurobiology of cognition in schizophrenia.
    Tamminga CA
    J Clin Psychiatry; 2006 Sep; 67(9):e11. PubMed ID: 17081078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Functional role of dopamine D4 receptor in schizophrenia].
    Semba J
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2004 Feb; 24(1):13-20. PubMed ID: 15027326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phencyclidine and genetic animal models of schizophrenia developed in relation to the glutamate hypothesis.
    Enomoto T; Noda Y; Nabeshima T
    Methods Find Exp Clin Pharmacol; 2007 May; 29(4):291-301. PubMed ID: 17609743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis.
    Kuroki T; Nagao N; Nakahara T
    Prog Brain Res; 2008; 172():199-212. PubMed ID: 18772034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Transmitter dysfunction in patients with schizophrenia. Significance for cognitive functioning and treatment].
    Glenthøj BY; Mackeprang T; Bille AE; Hemmingsen RP
    Ugeskr Laeger; 1999 Mar; 161(10):1391-8. PubMed ID: 10085745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dopamine D3 and D4 receptor antagonists in the treatment of schizophrenia.
    Jardemark K; Wadenberg ML; Grillner P; Svensson TH
    Curr Opin Investig Drugs; 2002 Jan; 3(1):101-5. PubMed ID: 12054059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phospholipase C-beta1 knockout mice exhibit endophenotypes modeling schizophrenia which are rescued by environmental enrichment and clozapine administration.
    McOmish CE; Burrows E; Howard M; Scarr E; Kim D; Shin HS; Dean B; van den Buuse M; Hannan AJ
    Mol Psychiatry; 2008 Jul; 13(7):661-72. PubMed ID: 17667964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blonanserin, an antipsychotic and dopamine D₂/D₃receptor antagonist, and ameliorated alcohol dependence.
    Takaki M; Ujike H
    Clin Neuropharmacol; 2013; 36(2):68-9. PubMed ID: 23503552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.